SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

TLDR

SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system. In vitro, SR141716A antagonises the inhibitory effects of cannabinoid receptor agonists on mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes, and after intraperitoneal or oral administration it blocks classical pharmacological and behavioural effects of cannabinoid receptor agonists. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor.

Abstract

SR141716A is the first selective and orally active antagonist of the brain cannabinoid receptor. This compound displays nanomolar affinity for the central cannabinoid receptor but is not active on the peripheral cannabinoid receptor. In vitro, SR141716A antagonises the inhibitory effects of cannabinoid receptor agonists on both mouse vas deferens contractions and adenylyl cyclase activity in rat brain membranes. After intraperitoneal or oral administration SR141716A antagonises classical pharmacological and behavioural effects of cannabinoid receptor agonists. This compound should prove to be a powerful tool for investigating the in vivo functions of the anandamide/cannabinoid system.